Evercore ISI initiated coverage on OnKure Therapeutics
$OKUR
Biotechnology: Pharmaceutical Preparations
Health Care
Evercore ISI initiated coverage of OnKure Therapeutics with a rating of Outperform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/30/2025 | Outperform | Evercore ISI | |
| 12/5/2024 | $33.00 | Outperform | Leerink Partners |
| 10/10/2024 | $35.00 | Outperform | Oppenheimer |
Evercore ISI initiated coverage of OnKure Therapeutics with a rating of Outperform
Leerink Partners initiated coverage of OnKure Therapeutics with a rating of Outperform and set a new price target of $33.00
Oppenheimer initiated coverage of OnKure Therapeutics with a rating of Outperform and set a new price target of $35.00
3 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
-- Announced nomination of OKI-355, a next-generation PI3Kα pan-mutant selective inhibitor candidate, in vascular anomalies -- Initiated a discovery research program to expand the company's pipeline in vascular anomalies -- Announced nomination of OKI-345, a next generation PI3Kα pan-mutant selective inhibitor candidate, in breast cancer -- Closed $150 million private placement to advance next-generation PI3Kα pan-mutant programs into clinical development in 2027 -- $192 million cash and cash equivalents as of March 31, 2026, expected to fund operations into 2029 BOULDER, Colo., May 05, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutica
-- Financing led by Access Biotechnology with participation from new and existing investors -- Financing to support advancement of two next-generation PI3Kα pan-mutant inhibitors for breast cancer and vascular anomalies – expect to file INDs for each program in 1H 2027 -- Liam Ratcliffe Joins OnKure's Board of Directors BOULDER, Colo., March 27, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it has entered into a securities purchase agreement for a private placement with certain institutional and accredited healthcare investors, raising gross proceeds of a
-- First patients dosed in triplet expansion arms of the PIKture-01 trial evaluating OKI-219 in combination with fulvestrant and ribociclib, and in combination with trastuzumab and tucatinib in patients with metastatic breast cancer -- Clinical data from OKI-219 PIKture-01 single agent and fulvestrant combination arms are maturing and is now expected to be reported together with initial data from the triplet expansion arms in the first quarter of 2026 -- Significant progress in next-generation PI3Kα pan-mutant inhibitor program; multiple candidates identified - announcement planned for the first quarter of 2026 -- Expansion into Vascular Malformations - additional information to be provid
4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
S-8 - OnKure Therapeutics, Inc. (0001637715) (Filer)
8-K - OnKure Therapeutics, Inc. (0001637715) (Filer)
SCHEDULE 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)
BOULDER, Colo., Nov. 25, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that posters selected for presentation at the 2024 San Antonio Breast Cancer Symposium (SABCS), including the poster presenting the preliminary data from the Company's first-in-human PIKture-01 trial of OKI-219, will be published to the symposium's virtual meeting platform for registered attendees on December 10th. OnKure will now hold its investor call to review preliminary data from the PIKture-01 study of OKI-219 on Tuesday, December 10, 2024 at 7:00 a.m. CT (8:00 a.m. E
-- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported -- Initial patient data show exposures of OKI-219 exceeding levels associated with robust antitumor activity in preclinical models -- Data support the initiation of Part 1b of PIKture-01 evaluating OKI-219 in combination with fulvestrant; first patients dosed, and initial data are expected in 2H-2025 -- Management to host conference call today, December 10, 2024 at 7:00 a.m. CT BOULDER, Colo., Dec. 10, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medi
OnKure to host a conference call to review key data presented at SABCS and provide a general corporate update on Friday, December 13, 2024 at 8:00 a.m. ET BOULDER, Colo., Nov. 01, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that two abstracts discussing preliminary clinical data and preclinical data for OKI-219, a potential best-in-class, mutant-selective PI3KαH1047R inhibitor, have been selected for presentation during poster sessions at the 2024 San Antonio Breast Cancer Symposium (SABCS), which is being held virtually and in person from D
SC 13G/A - OnKure Therapeutics, Inc. (0001637715) (Subject)
SC 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)
SC 13G/A - OnKure Therapeutics, Inc. (0001637715) (Subject)